Topics
A to Z
Data &
 Statistics
Forms &
Publications
News &
Advisories
Licensing &
Certification
Rules &
Regulations
Public Health
Directory
Print this Article   Bookmark and Share
Pharmacy Resources for Immunization

NOTICE:
Implementation date was January 1, 2014.

For each vaccine encounter, prior to administering vaccine, pharmacy personnel will look up each patient in the ALERT Immunization Information System (IIS) to determine the patient's vaccine history and to forecast vaccines needed.

Exceptions:

  • This is not required when administering only influenza vaccines, but will continue to be recommended to help increase pneumococcal vaccine rates.
  • This is not required when the pharmacy/pharmacist conducts a remote vaccine clinic, but will continue to be recommended when remote connectivity is available.

Regarding Zostavax® and Adults age 50 and older:

Update based upon the August 22, 2014 MMWR

On August 22, 2014 ACIP made the following determinations:

  1. Not to recommend Zostavax for persons <60 years of age.
  2. The burden of herpes zoster increases with age, especially after age 60.
  3. Adults receiving herpes zoster vaccine before age 60 years might not be protected when the risks for herpes zoster and its complications are the highest.
  4. Vaccination at age 60 years would prevent the most shingles cases (26,147 per 1 million persons).
  5. The protection of herpes zoster vaccine wanes within the first 5 years after vaccination.
  6. Booster doses have not been studied.
  7. The CDC is actively monitoring data on duration of vaccine protection in adults vaccinated at age ≥60 years. As additional data become available, ACIP will reevaluate the optimal age for vaccination and the need for revaccination.
  8. Zostavax is covered by some Medicare Part D policies for patients ≥65 years of age. Oregon Medicaid covers zoster vaccine for those age 60 and older. Other insurance companies may not cover the cost of Zostavax, especially for indications (e.g., <60 years of age) that lie outside of ACIP recommendations.

Additional Resources